Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

The FDA has approved Atzumi (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.

DHE is a migraine-specific acute medication first approved in 1946. The FDA's approval of the nasal powder formulation, ...

Previously called STS101, the company said Wednesday that the drug’s brand name is Atzumi and is indicated for acute migraine ...

A Utah manufacturer says the truth prevailed. But a former federal regulator believes the dismissal of the case against Xlear ...